Tin tức & Cập nhật

Chỉ hiển thị Multimedia

Real-world data confirm effectiveness of dupilumab in eosinophilic esophagitis

10 Jun 2026

Dupilumab has been shown to reduce symptomatic, endoscopic, and histological eosinophilic esophagitis (EoE) markers for patients treated in routine practice, as shown in the retrospective DUPEOETALY study.

Real-world data confirm effectiveness of dupilumab in eosinophilic esophagitis

10 Jun 2026

One in five patients with chronic HBV infection achieves functional cure with bepirovirsen

10 Jun 2026 bởi

The novel antisense oligonucleotide bepirovirsen has induced functional cure in one-fifth of patients with chronic hepatitis B virus (HBV) infection in the phase 3 B-Well 1 and B-Well 2 trials.

One in five patients with chronic HBV infection achieves functional cure with bepirovirsen

10 Jun 2026

$TNFi, IL-17i reduce risk of osteoporosis, but not hip fracture, in r-axSpA patients$

TNFi, IL-17i reduce risk of osteoporosis, but not hip fracture, in r-axSpA patients

10 Jun 2026

Patients with radiographic axial spondyloarthritis (r-axSpA) who have been exposed to tumour necrosis factor inhibitor (TNFi) and interleukin (IL)-17 inhibitor (IL-17i) appear to have a lower risk of osteoporosis, but not hip fracture, than biologic disease-modifying antirheumatic drug (bDMARD)-naïve individuals, a recent study has shown.

TNFi, IL-17i reduce risk of osteoporosis, but not hip fracture, in r-axSpA patients

10 Jun 2026

LNF-based regimens may alter trajectory of CHD treatment

10 Jun 2026 bởi

Individuals with chronic hepatitis D (CHD) may benefit from lonafarnib boosted with ritonavir (LNF/RTV) alone or in combination with peg-interferon-alfa (PEG), findings from the phase III D-LIVR trial have shown.

LNF-based regimens may alter trajectory of CHD treatment

10 Jun 2026

$Lutikizumab shows promise in refractory hidradenitis suppurativa$

Lutikizumab shows promise in refractory hidradenitis suppurativa

10 Jun 2026

Treatment with lutikizumab appears to improve outcomes in patients with moderate-to-severe hidradenitis suppurativa (HS) who have not responded to anti-TNF therapy, according to a phase II trial.

Lutikizumab shows promise in refractory hidradenitis suppurativa

10 Jun 2026

Tezepelumab cuts oral corticosteroid use without compromising asthma control

09 Jun 2026 bởi

Tezepelumab demonstrates steroid-sparing potential in patients with severe asthma, reducing maintenance oral corticosteroid use while maintaining asthma control, as shown in the phase III SUNRISE study.

Tezepelumab cuts oral corticosteroid use without compromising asthma control

09 Jun 2026

Rapid response to obesity medications tied to greater weight loss

09 Jun 2026 bởi

A post hoc analysis of the SURMOUNT-5 study reveals more tirzepatide-treated individuals with obesity achieving all body weight (BW) reduction thresholds than semaglutide-treated participants, with rapid responders showing a greater magnitude of weight loss.

Rapid response to obesity medications tied to greater weight loss

09 Jun 2026

Daraxonrasib makes history in one of the deadliest cancers

09 Jun 2026 bởi

Daraxonrasib—an oral, potent RAS(ON) multi-selective, tri-complex inhibitor—demonstrates unprecedented survival benefits in individuals with previously treated metastatic pancreatic adenocarcinoma (mPDAC) in the landmark phase III RASolute 302 study.

Daraxonrasib makes history in one of the deadliest cancers

09 Jun 2026

Oral semaglutide provides limited benefit in individuals with early AD

09 Jun 2026

The use of oral semaglutide does not reduce the speed of clinical progression in individuals with early Alzheimer's disease (AD), according to the results to two phase III trials.

Oral semaglutide provides limited benefit in individuals with early AD

09 Jun 2026

Glycaemic control in T2D better with CGM vs self-monitoring

08 Jun 2026 bởi

In adult patients with type 2 diabetes (T2D) receiving basal insulin alongside other glucose-lowering medications, real-time continuous glucose monitoring (CGM) demonstrates superiority over self-monitoring of blood glucose (SMBG) in terms of optimizing glycaemic control, according to the FreeDM2 study.

Glycaemic control in T2D better with CGM vs self-monitoring

08 Jun 2026

Tin tức & Cập nhật

Xem bài viết Dược

Xem

Chuyên ngành:

Real-world data confirm effectiveness of dupilumab in eosinophilic esophagitis

Real-world data confirm effectiveness of dupilumab in eosinophilic esophagitis

One in five patients with chronic HBV infection achieves functional cure with bepirovirsen

One in five patients with chronic HBV infection achieves functional cure with bepirovirsen

TNFi, IL-17i reduce risk of osteoporosis, but not hip fracture, in r-axSpA patients

TNFi, IL-17i reduce risk of osteoporosis, but not hip fracture, in r-axSpA patients

LNF-based regimens may alter trajectory of CHD treatment

LNF-based regimens may alter trajectory of CHD treatment

Lutikizumab shows promise in refractory hidradenitis suppurativa

Lutikizumab shows promise in refractory hidradenitis suppurativa

Tezepelumab cuts oral corticosteroid use without compromising asthma control

Tezepelumab cuts oral corticosteroid use without compromising asthma control

Rapid response to obesity medications tied to greater weight loss

Rapid response to obesity medications tied to greater weight loss

Daraxonrasib makes history in one of the deadliest cancers

Daraxonrasib makes history in one of the deadliest cancers

Oral semaglutide provides limited benefit in individuals with early AD

Oral semaglutide provides limited benefit in individuals with early AD

Glycaemic control in T2D better with CGM vs self-monitoring

Glycaemic control in T2D better with CGM vs self-monitoring